Discover
Clinical Minds
Clinical Minds
Author: Medidata
Subscribed: 4Played: 12Subscribe
Share
© Medidata
Description
Go behind the scenes of clinical research with some of the leading minds in life sciences. Discover what’s happening in today’s world of clinical trials, the technology and ideas transforming them, and why it matters for each and every one of us. This is Clinical Minds, presented by Medidata.
15 Episodes
Reverse
Is your product truly inspired by patient insights? Patient centricity is more than just a buzzword: it’s a movement. So how do you make sure your products improve the patient experience in clinical trials and alleviate patient burden?
In this episode, industry experts Kelly McKee and Alicia Staley are joined by Paul Chang, VP of Design at Medidata, to map the future of product design in clinical trials. Learn how Medidata’s patient advocates directly impact UX design to drive patient centricity across products.
Paul has spent over 20 years across a diverse range of product and design initiatives. In his role as VP of Design, he is responsible for how products and services are experienced by customers, partners, clinicians, and patients; this includes leading design strategy and building Medidata’s capabilities and reputation as a design-driven company.
As a patient, who owns your clinical trial data? Patient participation is the foundation of clinical trial research. But in today’s world, patient access to data is limited and siloed. How do researchers ensure patient data return is the standard operating procedure and information is shared with trial participants?
In this episode, Craig Lipset sits down with Kelly McKee and Alicia Staley of Medidata to discuss the challenges of data return and how to improve patient access and clinical trial data transparency.
Craig is an advisor, educator, advocate, and innovator focused on novel solutions for clinical trials and medicine development. He is the founder of Clinical Innovation Partners, Co-Chair for the Decentralized Trials & Research Alliance, and Vice Chair of the MedStar Health Research Institute.
The U.S. population is growing increasingly diverse and ensuring that we have meaningful representation of racial and ethnic minorities and other diverse populations in clinical trials for regulated medical products is fundamental not only to FDA's regulatory mission, but also public health,” Dr. Jovonni Spinner, Associate Director of Outreach and Communications at the FDA's Office of Minority Health and Health Equity.
Related links
https://www.fda.gov/about-fda/office-commissioner/office-minority-health-and-health-equity
https://www.beaconpublichealth.com/
The simplest thing to do is to find out what kind of patients you have. Find out what cultures they are. Learn about the culture. Learn to connect. Be a human. Don't just be a robot that does science. Don't speak above someone's level. Speak to them. Put yourself in that patient's shoes, and speak to them kindly,” says Dr. Fabian Sandoval, CEO and Research Director of the Emerson Clinical Research Institute in Washington, DC, and Emmy winner and host of the weekly medical TV show "Tu Salud, Tu Familia
Currently our black and brown communities are really grossly underrepresented in cancer clinical trials, and we need to fix that. Historical barriers around egregious medical behaviors that have taken place in the past, cultural barriers, language barriers, and finally socioeconomic barriers impact the outcome of someone’s cancer journey,” says Dana Dornsife, founder and CEO at Lazarex Cancer Foundation, a nationwide non-profit org she founded in 2006.








